Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Versartis Inc (VSAR) Finally Having The Breakout Hedge Funds Were Waiting For

Versartis Inc (NASDAQ:VSAR) is one of the top gainers today, as its shares have soared by nearly 30% in afternoon trading Monday. The huge push for the shares comes after it was announced this morning that the FDA had removed a partial clinical hold on the trial testing of Versartis’ VRS-317, which has set the company back on track to be the first to market with an rhGH (recombinant human growth hormone) treatment for those with growth hormone deficiency (GHD).


“Our team has continued to work diligently with the FDA and we are excited to be moving forward with the Phase 3 clinical trial of VRS-317 in pediatric GHD patients. There is a significant need for these patients to have treatment options that are less burdensome than the daily injections that are the current standard of care. We continue to expect VRS-317 to be the first and longest-acting rhGH product candidate in development to reach the market and, with the removal of the partial clinical hold, we remain on track to achieve this goal,” President and Chief Executive Officer Jay Shepard said in a press release announcing the news.

Despite the big gains today, Versartis Inc (NASDAQ:VSAR), which went public back in March of 2014, is still down by more than 15% this year and more than 39% lifetime. Shares of Versartis were particularly hard hit in early May when the company announced the FDA had placed the VRS-317 trial on partial clinical hold as it waited for additional bioanalytical data.

At the time, Versartis expressed that it would attempt to minimize any delays in its trial programs by continuing to recruit participants during that time, with the firm anticipating its enrolment in the phase 3 VELOCITY trial targeting GHD in children would be completed by the middle of 2016, and that 12-month, top line trial data from that study would be available by the middle of 2017.  The company reasserted those timelines today, noting that potential FDA approval for its lead drug candidate could be sought as early as late-2018. A separate clinical trial for GHD in adults has completed phase 1 testing.

The latest surge doesn’t seem to have caught hedge funds off guard, who were showing some bullish signs on the company in the first quarter of the year. The number of hedge funds with positions in the company increased to 15 from 10, while the total value of their holdings increased to $187.42 million from $184.55 million, despite shares of Versartis Inc (NASDAQ:VSAR) declining by over 18% during the first quarter. Shares are now up by about 3% since the end of the first quarter.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.